Difficulty: Medium
Average Score: 90%
Practice
A child born with Trisomy 21 should be evaluated for which associated cardiac manifestation?
Correct answer
B
Rationale
In the context of pharmacology and pediatric cardiovascular conditions, it is crucial to understand the cardiac manifestations associated with genetic conditions such as Trisomy 21 (Down syndrome). The correct answer is B) Congenital heart defect. Children with Trisomy 21 have a significantly higher risk of congenital heart defects compared to the general population.
This association is well-documented, with up to 50% of children with Down syndrome having some form of congenital heart anomaly. These defects can range from atrial septal defects (ASD), ventricular septal defects (VSD), atrioventricular septal defects (AVSD), to more complex anomalies. Therefore, it is imperative to evaluate children with Trisomy 21 for these cardiac abnormalities early on to provide appropriate management and interventions.
Now, let's analyze why the other options are incorrect:
A) Systemic hypertension: While individuals with Down syndrome may develop hypertension later in life, it is not a primary cardiac manifestation associated with Trisomy 21 in pediatric patients.
C) Hyperlipidemia: Although individuals with Down syndrome are at increased risk of developing hyperlipidemia, this is not a cardiac manifestation but rather a metabolic concern.
D) Cardiomyopathy: Cardiomyopathy is not a commonly associated cardiac manifestation in children with Trisomy 21. Congenital heart defects are more prevalent in this population.
In an educational context, understanding these cardiac manifestations in pediatric patients with genetic conditions like Trisomy 21 is essential for nurses and healthcare providers involved in their care. Early identification and appropriate management of congenital heart defects can significantly impact the long-term health outcomes and quality of life for these individuals.
This association is well-documented, with up to 50% of children with Down syndrome having some form of congenital heart anomaly. These defects can range from atrial septal defects (ASD), ventricular septal defects (VSD), atrioventricular septal defects (AVSD), to more complex anomalies. Therefore, it is imperative to evaluate children with Trisomy 21 for these cardiac abnormalities early on to provide appropriate management and interventions.
Now, let's analyze why the other options are incorrect:
A) Systemic hypertension: While individuals with Down syndrome may develop hypertension later in life, it is not a primary cardiac manifestation associated with Trisomy 21 in pediatric patients.
C) Hyperlipidemia: Although individuals with Down syndrome are at increased risk of developing hyperlipidemia, this is not a cardiac manifestation but rather a metabolic concern.
D) Cardiomyopathy: Cardiomyopathy is not a commonly associated cardiac manifestation in children with Trisomy 21. Congenital heart defects are more prevalent in this population.
In an educational context, understanding these cardiac manifestations in pediatric patients with genetic conditions like Trisomy 21 is essential for nurses and healthcare providers involved in their care. Early identification and appropriate management of congenital heart defects can significantly impact the long-term health outcomes and quality of life for these individuals.